Increasing Prevalence of Bacterial Infections Has Propelled the Growth of the Vancomycin Market in the APAC Region!

The APAC vancomycin market has been experiencing significant growth in recent years. One of the key drivers of this growth is the increasing prevalence of antibiotic-resistant infections, such as MRSA and C. difficile. Vancomycin is an important antibiotic used to treat these infections, and as such, demand for the drug has been on the rise. Additionally, the large aging population in APAC has contributed to the growth of the vancomycin market, as elderly individuals are more susceptible to infections and often require antibiotic treatment. The increasing incidence of hospital-acquired infections, the growing number of surgeries, and the high prevalence of tuberculosis, which is often treated with antibiotics like vancomycin. These factors are driving the growth of the vancomycin market in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), the rate of TB disease among Asian persons is 14.4 cases per 100,000 persons. Furthermore, the rise in healthcare expenditure in APAC has led to greater access to healthcare services and increased demand for antibiotics, including vancomycin.

Access sample report (including graphs, charts, and figures):https://univdatos.com/get-a-free-sample-form-php/?product_id=38577

Further, the APAC Vancomycin Market is expected to grow at a strong CAGR of 7% during the forecast period (2022-2030). APAC is anticipated to emerge as the fastest-growing vancomycin market primarily owing to the growing population, increasing healthcare spending, and several countries in Asia, such as China and India, are considered emerging markets with significant growth potential for pharmaceuticals.

Based on type, the vancomycin market is bifurcated into wire daptomycin, linezolid, quinupristin, ampicillin, chloramphenicol, and others. The linezolid category is expected to grow at the fastest growth of this market during the forecast period. Linezolid is effective against certain strains of bacteria that are resistant to other antibiotics, including vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). As the incidence of these infections continues to rise in Asia, there is an increasing demand for effective treatments like linezolid.

For a detailed analysis of the Global Vancomycin Market browse through –https://univdatos.com/report/vancomycin-market/

By application, the market is bifurcated into sepsis, lung infection, skin soft tissue infection, colitis & intestinal inflammation, and others. Among these, the lung infection category captured the majority share of the vancomycin market in the region. This is mainly due to the rising cases of pneumonia, tuberculosis, and other infectious diseases contributing to the growth of this market. For instance, as per the National Institutes of Health (NIH), India has a higher prevalence of childhood pneumonia than any other country and is responsible for 20% of all child mortality worldwide due to pneumonia.

Global Vancomycin Market Segmentation

Market Insight, by Type

· Daptomycin

· Linezolid

· Quinupristin

· Ampicillin

· Chloramphenicol

· Others

Market Insights, by Application

· Sepsis

· Lung Infection

· Skin Soft Tissue Infection

· Colitis & Intestinal Inflammation

· Others

Market Insight, by Region

· North America

o U.S.

o Canada

o Rest of North America

· Europe

o Germany

o UK

o France

o Italy

o Spain

o Rest of Europe

· APAC

o China

o India

o Japan

o Rest of APAC

· Rest of the World

Top Company Profiles

· Pfizer Inc.

· Lilly

· Viamericas Corporation

· Alvogen

· Aphios Corporation

· Enanta Pharmaceuticals, Inc.

· LEGOCHEM BIOSCIENCES, Inc.

· LYTIX BIOPHARMA AS

· MGB Biopharma

· Microbiotix